American International Group, Inc. Bio Atla, Inc. Transaction History

American International Group, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$1.88 - $3.46 $351 - $647	-187 Reduced 0.85%	21,799 $74,000
Q4 2023 Feb 13, 2024	SELL	$1.27 - $3.18 $113 - $283	-89 Reduced 0.4%	21,986 $54,000
Q3 2023 Nov 13, 2023	BUY	$1.7 - $3.07 $1,334 - $2,409	785 Added 3.69%	22,075 $37,000
Q2 2023 Aug 04, 2023	BUY	$2.83 - $3.87 $60,250 - $82,392	21,290 New	21,290 $63,000
Q2 2022 Aug 12, 2022	SELL	$2.13 - $5.38 $16,415 - $41,463	-7,707 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$4.38 - $18.78 $2,378 - $10,197	-543 Reduced 6.58%	7,707 $39,000
Q4 2021 Feb 11, 2022	SELL	$19.0 - $30.95 $4,674 - $7,613	-246 Reduced 2.9%	8,250 $162,000
Q3 2021 Nov 12, 2021	BUY	$29.44 - $43.74 $49,105 - $72,958	1,668 Added 24.43%	8,496 $250,000
Q2 2021 Aug 13, 2021	BUY	$38.07 - $56.17 $2,969 - $4,381	78 Added 1.16%	6,828 $289,000
Q1 2021 May 07, 2021	BUY	$32.41 - $70.91 $218,767 - $478,642	6,750 New	6,750 $343,000

22.1M

10.7K

7.4K

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $59.2M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.